Before Korinna joined InflaRx in January 2019 she worked over 20 years in roles of increasing responsibility in academia and several biotech and pharmaceutical institutions, including Innate Pharma, Boehringer Ingelheim, Roche, Merck KGaA and Bayer. She is a physician-scientist with vast experience in clinical development. During her entire career, Korinna’s focus has been on Haemato-Oncology, Immunology and therapeutic vaccination.
Over the past 15 years Korinna developed NBE’s and NCE’s. She established successful international clinical development plans and led international, multi-cultural program/project groups responsible for execution of a broad spectrum of clinical studies, including first-in-human and phase 1 to phase III studies. She was pivotal in gaining marketing approval for Erbitux in Japan and contributed to the clinical development of substances such as IPH4102, volasertib, and Avastin.
Korinna is a licensed Medical Doctor and holds a Diploma in Biology from the University of Düsseldorf. She is a member of ASCO, ESMO, AACR and IASLC. She founded her scientific and clinical career at the University of Düsseldorf.